Equities analysts forecast that Akari Therapeutics (NASDAQ:AKTX) will report earnings per share of ($1.00) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Akari Therapeutics’ earnings. Akari Therapeutics posted earnings per share of ($0.09) during the same quarter last year, which would suggest a negative year over year growth rate of 1,011.1%. The company is scheduled to report its next quarterly earnings results on Monday, May 21st.
According to Zacks, analysts expect that Akari Therapeutics will report full year earnings of ($2.00) per share for the current financial year, with EPS estimates ranging from ($3.00) to ($1.00). For the next fiscal year, analysts expect that the firm will post earnings of ($2.00) per share, with EPS estimates ranging from ($3.00) to ($1.00). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Akari Therapeutics.
Akari Therapeutics (NASDAQ:AKTX) last announced its quarterly earnings results on Wednesday, March 21st. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.66) by $0.59.
A number of analysts have commented on the stock. B. Riley assumed coverage on shares of Akari Therapeutics in a research note on Thursday, February 8th. They set a “neutral” rating and a $3.00 price target for the company. Canaccord Genuity decreased their price target on shares of Akari Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, March 29th. Finally, Zacks Investment Research downgraded shares of Akari Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 16th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. Akari Therapeutics currently has a consensus rating of “Hold” and an average target price of $4.63.
Shares of AKTX stock opened at $2.01 on Friday. The firm has a market cap of $23.67, a price-to-earnings ratio of -7.18 and a beta of -7.67. Akari Therapeutics has a 12 month low of $1.70 and a 12 month high of $22.20.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Millennium Management LLC boosted its holdings in Akari Therapeutics by 125.0% during the 4th quarter. Millennium Management LLC now owns 260,020 shares of the biopharmaceutical company’s stock worth $1,126,000 after acquiring an additional 144,477 shares during the last quarter. Endurant Capital Management LP purchased a new position in Akari Therapeutics during the 4th quarter worth $871,000. Finally, AWM Investment Company Inc. purchased a new position in Akari Therapeutics during the 4th quarter worth $2,962,000. 32.94% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: This piece was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/09/zacks-brokerages-expect-akari-therapeutics-aktx-to-post-1-00-eps.html.
About Akari Therapeutics
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome.
Get a free copy of the Zacks research report on Akari Therapeutics (AKTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.